LINE-1 ORF1p is a human transposon protein expressed at negligible levels in normal tissue but is pervasive in carcinomas and high-risk precursors, making it a potentially useful pan-cancer biomarker. Because ORF1p blood levels are very low, Taylor, Wu, and colleagues engineered and iteratively improved ultrasensitive assays that detect single ORF1p molecules in plasma. These plasma ORF1p assays were found to be highly specific, rapid, and inexpensive. Additionally, plasma ORF1p demonstrated potential utility in multiple clinical scenarios, with preliminary promise in early detection of ovarian cancer, early therapeutic response monitoring in gastric and esophageal cancers, and prognostic value in colorectal and gastroesophageal cancers.

See article, p. 2532.

PML nuclear bodies (NB) are disrupted by the PML-RARA oncogenic fusion protein in acute promyelocytic leukemia (APL). Arsenic trioxide (ATO) and retinoic acid treatments are curative in APL by driving PML-RARA degradation and PML NB reassembly, but the mechanisms behind ATO-enforced NB assembly...

You do not currently have access to this content.